RecruitingNCT06889454

Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS

The Effect of Different Treatment Options on Markers of Vascular, Myocardial and Endothelial Function in Women With Polycystic Ovary Syndrome and the Association With Metabolic and Hormonal Abnormalities of the Syndrome


Sponsor

Attikon Hospital

Enrollment

120 participants

Start Date

Feb 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The aim of the present study is to investigate a) the presence of subclinical markers of vascular, myocardial and endothelial function in women with PCOS b) the acute alterations in these markers during the oral glucose tolerance test (OGTT) c) the impact of potential treatment interventions in these markers.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called GLP-1 receptor agonist, Lifestyle modification, and others for people with hyperandrogenism, hyperinsulinism, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGLP-1 receptor agonist

30 women will receive lifestyle modification and GLP-1 receptor agonists

DRUGOral contraceptive

30 women will receive lifestyle modification and oral contraceptive

DRUGMetformin

30 women will receive lifestyle modification and metformin

OTHERLifestyle modification

30 women will receive only lifestyle modification


Locations(1)

Attikon University General Hospital

Chaïdári, Greece

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06889454


Related Trials